Pancreatic ductal adenocarcinoma (PDAC) frequently coexists with diabetes mellitus (DM), which is associated with worse prognosis. However, the impact of glycemic control on survival remains unclear. To address this, a study evaluated whether glycemic status influences overall survival (OS) in 255 PDAC patients with DM. Patients with HbA1c < 8% had longer median OS (2.5 years) compared with those with HbA1c ≥ 8% (1.2 years).
Among DM subtypes, long-standing DM was associated with the poorest survival (1.7 years), while type 3c DM patients fared best (7.2 years). In multivariable analysis, poor glycemic control (HR 1.54), age ≥ 65 (HR 1.83), stage IV disease (HR 2.04), and male sex (HR 1.52) independently predicted worse outcomes. These findings suggest that maintaining good glycemic control may improve survival in PDAC patients with diabetes, emphasizing its role in multidisciplinary…
